Lack of CD27 in myeloma delineates different presentation and outcome
Summary CD27 expression was evaluated on normal plasma cells (PC), PC from patients with multiple myeloma (MM) at diagnosis or relapse and on human myeloma cell lines (HMCL). CD27 was expressed by normal PC but was lacking in PC from MM patients at diagnosis (36%) and relapse (47%), and in HMCL (92%...
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2006-01, Vol.132 (2), p.168-170 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 170 |
|---|---|
| container_issue | 2 |
| container_start_page | 168 |
| container_title | British journal of haematology |
| container_volume | 132 |
| creator | Moreau, Philippe Robillard, Nelly Jégo, Gaétan Pellat, Catherine Gouill, Steven Le Thoumi, Soraya Avet‐Loiseau, Hervé Harousseau, Jean‐Luc Bataille, Régis |
| description | Summary
CD27 expression was evaluated on normal plasma cells (PC), PC from patients with multiple myeloma (MM) at diagnosis or relapse and on human myeloma cell lines (HMCL). CD27 was expressed by normal PC but was lacking in PC from MM patients at diagnosis (36%) and relapse (47%), and in HMCL (92%). The prognostic impact of CD27 expression was evaluated in 42 patients with de novo MM. Overall survival was 92% at 3 years in CD27+ vs. 50% in CD27– MM (P = 0·017). CD27 expression seems to delineate two important subsets of MM with different presenting features and clinical outcomes. |
| doi_str_mv | 10.1111/j.1365-2141.2005.05849.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67609947</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>979215061</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4249-e27a8a9f530d9ee9e81c1e9309fceb89039a3961feb3d38913c766a17585e1253</originalsourceid><addsrcrecordid>eNqNkMGO1DAMQCMEYoeFX0AREtxa7KZpkgMHdlhY0Ehc4BxlUkfq0DZD0oqdv6dlRqzECV9syc-W_RjjCCUu8fZQomhkUWGNZQUgS5C6NuX9I7b523jMNgCgCoRaX7FnOR8AUIDEp-wKG2F0I3HDbnfO_-Ax8O2HSvFu5MOJ-jg43lLfjeQmyrztQqBE48SPifKS3dTFkbux5XGefBzoOXsSXJ_pxSVfs-8fb79t74rd10-ft-93ha-r2hRUKaedCVJAa4gMafRIRoAJnvbagDBOmAYD7UUrtEHhVdM4VFJLwkqKa_bmvPeY4s-Z8mSHLnvqezdSnLNtVAPG1GoBX_0DHuKcxuU2i8vnqECKBdJnyKeYc6Jgj6kbXDpZBLt6tge76rSrTrt6tn882_tl9OVl_7wfqH0YvIhdgNcXwGXv-pDc6Lv8wKlaqRpW7t2Z-9X1dPrvA-zNl7u1Er8B8KGWaw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>198617053</pqid></control><display><type>article</type><title>Lack of CD27 in myeloma delineates different presentation and outcome</title><source>MEDLINE</source><source>Wiley Online Library Free Content</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Moreau, Philippe ; Robillard, Nelly ; Jégo, Gaétan ; Pellat, Catherine ; Gouill, Steven Le ; Thoumi, Soraya ; Avet‐Loiseau, Hervé ; Harousseau, Jean‐Luc ; Bataille, Régis</creator><creatorcontrib>Moreau, Philippe ; Robillard, Nelly ; Jégo, Gaétan ; Pellat, Catherine ; Gouill, Steven Le ; Thoumi, Soraya ; Avet‐Loiseau, Hervé ; Harousseau, Jean‐Luc ; Bataille, Régis</creatorcontrib><description>Summary
CD27 expression was evaluated on normal plasma cells (PC), PC from patients with multiple myeloma (MM) at diagnosis or relapse and on human myeloma cell lines (HMCL). CD27 was expressed by normal PC but was lacking in PC from MM patients at diagnosis (36%) and relapse (47%), and in HMCL (92%). The prognostic impact of CD27 expression was evaluated in 42 patients with de novo MM. Overall survival was 92% at 3 years in CD27+ vs. 50% in CD27– MM (P = 0·017). CD27 expression seems to delineate two important subsets of MM with different presenting features and clinical outcomes.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/j.1365-2141.2005.05849.x</identifier><identifier>PMID: 16398651</identifier><identifier>CODEN: BJHEAL</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>Aged ; Antigens, Neoplasm - blood ; Biological and medical sciences ; Biomarkers, Tumor - blood ; CD27 ; Female ; Hematologic and hematopoietic diseases ; Hematology ; Humans ; Immunodeficiencies. Immunoglobulinopathies ; Immunoglobulinopathies ; Immunopathology ; Immunophenotyping ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Medical sciences ; Middle Aged ; Multiple Myeloma - blood ; Multiple Myeloma - therapy ; myeloma ; Plasma Cells - immunology ; Prognosis ; Survival Analysis ; Treatment Outcome ; Tumor Cells, Cultured ; Tumor Necrosis Factor Receptor Superfamily, Member 7 - blood</subject><ispartof>British journal of haematology, 2006-01, Vol.132 (2), p.168-170</ispartof><rights>2006 INIST-CNRS</rights><rights>Copyright Blackwell Publishing Jan 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4249-e27a8a9f530d9ee9e81c1e9309fceb89039a3961feb3d38913c766a17585e1253</citedby><cites>FETCH-LOGICAL-c4249-e27a8a9f530d9ee9e81c1e9309fceb89039a3961feb3d38913c766a17585e1253</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2141.2005.05849.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2141.2005.05849.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,4024,27923,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17477401$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16398651$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moreau, Philippe</creatorcontrib><creatorcontrib>Robillard, Nelly</creatorcontrib><creatorcontrib>Jégo, Gaétan</creatorcontrib><creatorcontrib>Pellat, Catherine</creatorcontrib><creatorcontrib>Gouill, Steven Le</creatorcontrib><creatorcontrib>Thoumi, Soraya</creatorcontrib><creatorcontrib>Avet‐Loiseau, Hervé</creatorcontrib><creatorcontrib>Harousseau, Jean‐Luc</creatorcontrib><creatorcontrib>Bataille, Régis</creatorcontrib><title>Lack of CD27 in myeloma delineates different presentation and outcome</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Summary
CD27 expression was evaluated on normal plasma cells (PC), PC from patients with multiple myeloma (MM) at diagnosis or relapse and on human myeloma cell lines (HMCL). CD27 was expressed by normal PC but was lacking in PC from MM patients at diagnosis (36%) and relapse (47%), and in HMCL (92%). The prognostic impact of CD27 expression was evaluated in 42 patients with de novo MM. Overall survival was 92% at 3 years in CD27+ vs. 50% in CD27– MM (P = 0·017). CD27 expression seems to delineate two important subsets of MM with different presenting features and clinical outcomes.</description><subject>Aged</subject><subject>Antigens, Neoplasm - blood</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - blood</subject><subject>CD27</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematology</subject><subject>Humans</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>Immunophenotyping</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multiple Myeloma - blood</subject><subject>Multiple Myeloma - therapy</subject><subject>myeloma</subject><subject>Plasma Cells - immunology</subject><subject>Prognosis</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><subject>Tumor Cells, Cultured</subject><subject>Tumor Necrosis Factor Receptor Superfamily, Member 7 - blood</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMGO1DAMQCMEYoeFX0AREtxa7KZpkgMHdlhY0Ehc4BxlUkfq0DZD0oqdv6dlRqzECV9syc-W_RjjCCUu8fZQomhkUWGNZQUgS5C6NuX9I7b523jMNgCgCoRaX7FnOR8AUIDEp-wKG2F0I3HDbnfO_-Ax8O2HSvFu5MOJ-jg43lLfjeQmyrztQqBE48SPifKS3dTFkbux5XGefBzoOXsSXJ_pxSVfs-8fb79t74rd10-ft-93ha-r2hRUKaedCVJAa4gMafRIRoAJnvbagDBOmAYD7UUrtEHhVdM4VFJLwkqKa_bmvPeY4s-Z8mSHLnvqezdSnLNtVAPG1GoBX_0DHuKcxuU2i8vnqECKBdJnyKeYc6Jgj6kbXDpZBLt6tge76rSrTrt6tn882_tl9OVl_7wfqH0YvIhdgNcXwGXv-pDc6Lv8wKlaqRpW7t2Z-9X1dPrvA-zNl7u1Er8B8KGWaw</recordid><startdate>200601</startdate><enddate>200601</enddate><creator>Moreau, Philippe</creator><creator>Robillard, Nelly</creator><creator>Jégo, Gaétan</creator><creator>Pellat, Catherine</creator><creator>Gouill, Steven Le</creator><creator>Thoumi, Soraya</creator><creator>Avet‐Loiseau, Hervé</creator><creator>Harousseau, Jean‐Luc</creator><creator>Bataille, Régis</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><general>Blackwell Publishing Ltd</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>200601</creationdate><title>Lack of CD27 in myeloma delineates different presentation and outcome</title><author>Moreau, Philippe ; Robillard, Nelly ; Jégo, Gaétan ; Pellat, Catherine ; Gouill, Steven Le ; Thoumi, Soraya ; Avet‐Loiseau, Hervé ; Harousseau, Jean‐Luc ; Bataille, Régis</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4249-e27a8a9f530d9ee9e81c1e9309fceb89039a3961feb3d38913c766a17585e1253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Aged</topic><topic>Antigens, Neoplasm - blood</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - blood</topic><topic>CD27</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematology</topic><topic>Humans</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>Immunophenotyping</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multiple Myeloma - blood</topic><topic>Multiple Myeloma - therapy</topic><topic>myeloma</topic><topic>Plasma Cells - immunology</topic><topic>Prognosis</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><topic>Tumor Cells, Cultured</topic><topic>Tumor Necrosis Factor Receptor Superfamily, Member 7 - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moreau, Philippe</creatorcontrib><creatorcontrib>Robillard, Nelly</creatorcontrib><creatorcontrib>Jégo, Gaétan</creatorcontrib><creatorcontrib>Pellat, Catherine</creatorcontrib><creatorcontrib>Gouill, Steven Le</creatorcontrib><creatorcontrib>Thoumi, Soraya</creatorcontrib><creatorcontrib>Avet‐Loiseau, Hervé</creatorcontrib><creatorcontrib>Harousseau, Jean‐Luc</creatorcontrib><creatorcontrib>Bataille, Régis</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moreau, Philippe</au><au>Robillard, Nelly</au><au>Jégo, Gaétan</au><au>Pellat, Catherine</au><au>Gouill, Steven Le</au><au>Thoumi, Soraya</au><au>Avet‐Loiseau, Hervé</au><au>Harousseau, Jean‐Luc</au><au>Bataille, Régis</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lack of CD27 in myeloma delineates different presentation and outcome</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2006-01</date><risdate>2006</risdate><volume>132</volume><issue>2</issue><spage>168</spage><epage>170</epage><pages>168-170</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><coden>BJHEAL</coden><abstract>Summary
CD27 expression was evaluated on normal plasma cells (PC), PC from patients with multiple myeloma (MM) at diagnosis or relapse and on human myeloma cell lines (HMCL). CD27 was expressed by normal PC but was lacking in PC from MM patients at diagnosis (36%) and relapse (47%), and in HMCL (92%). The prognostic impact of CD27 expression was evaluated in 42 patients with de novo MM. Overall survival was 92% at 3 years in CD27+ vs. 50% in CD27– MM (P = 0·017). CD27 expression seems to delineate two important subsets of MM with different presenting features and clinical outcomes.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>16398651</pmid><doi>10.1111/j.1365-2141.2005.05849.x</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2006-01, Vol.132 (2), p.168-170 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67609947 |
| source | MEDLINE; Wiley Online Library Free Content; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals |
| subjects | Aged Antigens, Neoplasm - blood Biological and medical sciences Biomarkers, Tumor - blood CD27 Female Hematologic and hematopoietic diseases Hematology Humans Immunodeficiencies. Immunoglobulinopathies Immunoglobulinopathies Immunopathology Immunophenotyping Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Middle Aged Multiple Myeloma - blood Multiple Myeloma - therapy myeloma Plasma Cells - immunology Prognosis Survival Analysis Treatment Outcome Tumor Cells, Cultured Tumor Necrosis Factor Receptor Superfamily, Member 7 - blood |
| title | Lack of CD27 in myeloma delineates different presentation and outcome |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T15%3A55%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lack%20of%20CD27%20in%20myeloma%20delineates%20different%20presentation%20and%20outcome&rft.jtitle=British%20journal%20of%20haematology&rft.au=Moreau,%20Philippe&rft.date=2006-01&rft.volume=132&rft.issue=2&rft.spage=168&rft.epage=170&rft.pages=168-170&rft.issn=0007-1048&rft.eissn=1365-2141&rft.coden=BJHEAL&rft_id=info:doi/10.1111/j.1365-2141.2005.05849.x&rft_dat=%3Cproquest_cross%3E979215061%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=198617053&rft_id=info:pmid/16398651&rfr_iscdi=true |